Abstracts tagged "Inflammation"

Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: 306 • 2018 ACR/ARHP Annual Meeting
The Role of Inflammation in the Evolution of MRI Erosions in the Feet of Patients with Early RA
Hanyan Zou¹, Karen A. Beattie², Saara Totterman³, George Ioannidis¹ and Maggie Larche^2,4, ¹McMaster University, Hamilton, ON, Canada, ²Medicine, McMaster University, Hamilton, ON, Canada, ³Qmetrics Technologies, Pittsford, NY, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Patients with aggressive RA develop early structural damage. As persistent inflammation is associated with bone erosions, assessing inflammatory activity may be key in treatment…
Abstract Number: 1952 • 2018 ACR/ARHP Annual Meeting
Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway
Vishal Deshmukh, Timothy Seo and Yusuf Yazici, Samumed, LLC, San Diego, CA
Background/Purpose: Tendinopathy is an inflammatory and degenerative disorder caused by injuries and overuse. The Wnt pathway is upregulated in chronic tendinopathy and involved in inflammation,…
Abstract Number: 562 • 2018 ACR/ARHP Annual Meeting
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
Paul Emery¹, Gerd R. Burmester², Esperanza Naredo³, Ivan Lagunes Galindo⁴, Ying Zhang⁵, Xin Wang⁵, Maja Hojnik⁶ and Philip G. Conaghan⁷, ¹University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL, ⁶AbbVie, Ljubljana, Slovenia, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: ACR and EULAR recommend bDMARD tapering in patients (pts) with rheumatoid arthritis (RA) who achieved stable clinical remission. Yet, there are limited systematically collected…
Abstract Number: 1994 • 2018 ACR/ARHP Annual Meeting
Osteoarthritis Severity Is Reduced By Intra-Articular Administration of Hydrogen Sulfide
Elena F. Burguera^1,2, Angela Vela-Anero³, Carlos Vaamonde-Garcia³, Tamara Hermida-Gómez^1,2, Purificacion Filgueira-Fernandez^1,2, Lucía Gato-Calvo², Rosa Meijide-Failde⁴ and Francisco J Blanco⁵, ¹CIBER-BBN, Madrid, Spain, ²Unidad de Medicina Regenerativa, Grupo de Investigación en Reumatología, Agrupación Estratégica CICA-INIBIC, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade de A Coruña (UDC), A Coruña, Spain, ³Department of Physiotherapy, Medicine and Biological sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain, ⁴Department of Physiotherapy, Medicine and Biological Sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain, ⁵Grupo de Investigación en Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain
Background/Purpose: Hydrogen sulphide (H2S) is recognized as a therapeutic target in osteoarthritis (OA). Exogenous supplementation with synthetic salts in in vitro models of OA has…
Abstract Number: 757 • 2018 ACR/ARHP Annual Meeting
Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis
Huihua Ding¹, Cheng Ling², Roberto Bassi³, Shinji L Okitsu⁴, Julie A. DeMartino⁴ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Department of Rheumatology, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴TIP Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). This study investigates urinary galecting-3 binding protein…
Abstract Number: 2005 • 2018 ACR/ARHP Annual Meeting
Identification of a Human Cartilage Microbial DNA Signature and Characterization of Distinct Microbiome Profiles Associated with Osteoarthritis
Chris Dunn^1,2, Cassandra Velasco^1,3, Alexander Rivas⁴, Madison Andrews^3,5, Paul Jacob⁶ and Matlock A. Jeffries^2,7, ¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Oklahoma Sport Science and Orthopedics, Oklahoma City, OK, ⁷Department of Medicine, Division of Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Osteoarthritis (OA) is both the most common form of arthritis and a leading cause of chronic disability. Bacterial products, including lipopolysaccharide (LPS), have been…
Abstract Number: 796 • 2018 ACR/ARHP Annual Meeting
Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis
Wanlong Wu^1,2, Petra Hoederath¹, Eric Hachulla³, Paolo Airò⁴, Gabriele Valentini⁵, Marco Matucci Cerinic⁶, Franco Cozzi⁷, Gabriela Riemekasten⁸, Yannick Allanore⁹, Patricia Carreira¹⁰, Suzana Jordan¹¹ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ³Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁴Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁵Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁶Division of Rheumatology, Division of Rheumatology, University of Florence, Florence, Italy, ⁷Division of Rheumatology, Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ⁹Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ¹⁰Servicio de Reumatologia, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Anti-U1RNP antibodies can be detected in patients with systemic sclerosis (SSc). However, their prevalence and clinical correlation with organ-specific complications have not been well…
Abstract Number: 2006 • 2018 ACR/ARHP Annual Meeting
Murine Ear Wound Cartilage Superhealer Trait Is Associated with Gut Microbiota Changes and Is Transferable to Non-Healer Mice By Gut Microbiome Transplant
Chris Dunn^1,2, Cassandra Velasco^1,3, Madison Andrews^3,4, Alexander Rivas⁵ and Matlock A. Jeffries^2,6, ¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵University of Arkansas for Medical Sciences, Little Rock, AR, ⁶Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: MRL/MpJ mice are substantially protected from developing post-traumatic osteoarthritis (OA), a trait with strong correlation to the ability to heal ear wounds. Previous studies…
Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Jeffrey A. Sparks¹, Tracy Doyle², Jie Huang¹, Beatrice Pan², Elaine Fletcher², Ritu Gill³, Hiroto Hatabu², Mizuki Nishino⁴, David Murphy², Taysir Mahmoud², Christine K Iannaccone⁵, Michelle Frits², Bing Lu⁶, Ivan O. Rosas⁷, Paul Dellaripa², Michael E Weinblatt⁵, Elizabeth Karlson⁶ and Nancy A. Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Beth-Israel Deaconess Medical Center, Boston, MA, ⁴Dana-Farber Cancer Institute, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁷BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…
Abstract Number: 2067 • 2018 ACR/ARHP Annual Meeting
Dysbiosis-Dependent Inflammasomes Activation Drives Innate Immune Responses in Ankylosing Spondylitis Patients
Francesco Ciccia¹, Giuliana Guggino¹, Aroldo Rizzo², Stefania Raimondo³, Simon Milling⁴ and Riccardo Alessandro³, ¹Rheumatology Unit, University of Palermo, Palermo, Italy, ²Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy, ³University of Palermo, Palermo, Italy, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: A growing body of evidences indicate that the aberrant activation of innate immune systems, occurring in genetically predisposed patients, drives inflammatory processes in Ankylosing…
Abstract Number: 905 • 2018 ACR/ARHP Annual Meeting
Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroeder⁵, Brian Kabat⁵, Carol Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Philip Seo⁹, Robert F. Spiera¹⁰, Eugene William St. Clair¹¹, Fernando Fervenza¹², John H. Stone¹³, Paul A. Monach¹⁴, Ulrich Specks¹⁵ and Peter A. Merkel¹⁶, ¹Pulmonary and Critical Care, Mayo Clinic College of Medicine, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medicine, Duke University Medical Center, Durham, NC, ¹²Nephrology, Mayo Clinic, Rochester, MN, ¹³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁵Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The deregulated overproduction of interleukin (IL)-6 has been implicated in several inflammatory and antibody-mediated autoimmune diseases. We aimed to investigate serum IL-6 levels (sIL-6)…
Abstract Number: 2073 • 2018 ACR/ARHP Annual Meeting
Role of miRNA-21-5p As a Potential Biomarker for the Inflammation Pathway in Psoriatic Disease and Response to Methotrexate Treatment
Rohan Machhar¹, Justine Y. Ye², Vinod Chandran² and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. miRNAs are small non coding RNAs whose main function, at a post…
Abstract Number: 990 • 2018 ACR/ARHP Annual Meeting
Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction
Mahamudul Haque¹, Anil K. Singh¹ and Salahuddin Ahmed^1,2, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: Guanylate binding protein 5 (GBP5), an interferon gamma (IFN-γ) inducible protein, helps to defend against invading pathogens. However, its role and properties beyond anti-viral…
Abstract Number: 2075 • 2018 ACR/ARHP Annual Meeting
Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients
Michael Gashick¹, Todd Wechter², Tessa Barrett¹, Sarah Azarchi², Stuart Katz³, Andrea L. Neimann⁴, James Krueger⁵, Sanja Jelic⁶, Edward Fisher¹, Jose U. Scher⁷ and Jeffrey S. Berger⁸, ¹Medicine/Cardiology, New York University School of Medicine, New York City, NY, ²Dermatology, New York University School of Medicine, New York City, NY, ³Medicine/Cardiology, New York University School of Medicine, New York, NY, ⁴Department of Dermatology, New York University School of Medicine, New York, NY, ⁵The Rockefeller University, New York, NY, ⁶Medicine/Pulmonary, Columbia University Medical Center, New York City, NY, ⁷New York University School of Medicine, New York, NY, ⁸Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) and Psoriasis (PsO) are chronic inflammatory diseases associated with vascular inflammation and increased CVD risk. Few studies have examined vascular inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].